SCHEMBL1504096

SCHEMBL1504096

O=C(O)CSCCN(CC(=O)O)CC(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.56
EYA2 O00167 1/20 0.56
APP P05067 1/20 0.56
ACE P12821 1/20 0.56
BLM P54132 3/20 0.54
PMP22 Q01453 2/20 0.54
CYP2C19 P33261 2/20 0.54
LMNA P02545 2/20 0.54
KDM4E B2RXH2 1/20 0.54
CHRM2 P08172 1/20 0.54
ADRA2A P08913 1/20 0.54
ALOX15 P16050 1/20 0.54
TSHR P16473 1/20 0.54
DRD1 P21728 1/20 0.54
SLC6A2 P23975 1/20 0.54
SLC6A4 P31645 1/20 0.54
ADRA1A P35348 1/20 0.54
DRD3 P35462 1/20 0.54
SLC6A3 Q01959 1/20 0.54
HRH3 Q9Y5N1 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3926050 0.88 TDP1 (0.65) TDP1EYA2APPACEBLM
SCHEMBL3930821 0.86 TDP1 (0.62) TDP1EYA2APPACEBLM
SCHEMBL890300 0.80 MAPT (0.50) BLMCYP2C19CHRM2TSHRCYP2D6
SCHEMBL2471304 0.74 TDP1 (0.59) TDP1EYA2APPACEBLM
SCHEMBL9525485 0.74 CYP2D6 (0.50) TDP1BLMCYP2C19LMNATSHR
Edetic Acid SCHEMBL1373 0.74 TDP1 (1.00) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL8607480 0.74 TDP1 (1.00) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL15136 0.74 TDP1 (1.00) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL8624198 0.74 TDP1 (1.00) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL16714076 0.74 TDP1 (1.00) TDP1EYA2APPACEBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040126344-A1 Compositions having glycolipid to lighten skin and alter post-inflammatory hyperpigmentation AVON PRODUCTS, INC. 2004-07-01 US claimed
US-12156832-B2 Method, and system for multi-layer cosmetic pads and use thereof ELC MANAGEMENT LLC (US) 2024-12-03 US disclosed
EP-4087441-A1 METHOD, AND SYSTEM FOR MULTI-LAYER COSMETIC PADS AND USE THEREOF ELC Management LLC (US) 2022-11-16 EP disclosed
WO-2021141926-A1 METHOD, AND SYSTEM FOR MULTI-LAYER COSMETIC PADS AND USE THEREOF ELC MANAGEMENT LLC (US) 2021-07-15 WO disclosed
US-20210205125-A1 Method, And System For Multi-Layer Cosmetic Pads and Use Thereof ELC MANAGEMENT LLC 2021-07-08 US disclosed
EP-2969030-B1 A TOPICAL LIGHTENING COMPOSITION AND METHODS OF USE THEREOF AVON PROD INC (US) 2021-01-13 EP disclosed
US-10117821-B2 Topical lightening composition and methods of use thereof AVON PRODUCTS, INC. (US) 2018-11-06 US disclosed
EP-2473183-B1 COSMETIC USES OF MODIFIED STRESSED YEAST EXTRACTS AND RELATED COMPOSITIONS AVON PROD INC (US) 2018-06-27 EP disclosed
EP-3148651-A1 TOPICAL LIGHTENING COMPOSITION AND METHODS OF USE THEREOF Avon Products, Inc. (US) 2017-04-05 EP disclosed
EP-2890359-B1 DICKKOPF-1 EXPRESSION MODULATING COMPOSITIONS AND USES THEREOF AVON PROD INC (US) 2016-10-05 EP disclosed
US-20140065086-A1 Dickkopf-1 Expression Modulating Compositions and Uses Thereof AVON PRODUCTS, INC. (US) 2014-03-06 US disclosed
US-8575106-B2 Cosmetic uses of modified stressed yeast extracts and related compositions AVON PRODUCTS, INC. (US) 2013-11-05 US disclosed
EP-2473183-A2 COSMETIC USES OF MODIFIED STRESSED YEAST EXTRACTS AND RELATED COMPOSITIONS Avon Products, Inc. (US) 2012-07-11 EP disclosed
EP-1572223-B1 USE OF ACTIVE EXTRACTS TO IMPROVE THE APPEARANCE OF SKIN, LIPS, HAIR AND/OR NAILS AVON PROD INC (US) 2011-06-22 EP disclosed
US-20110052517-A1 Cosmetic Uses of Modified Stressed Yeast Extracts and Related Compositions Avon Place (US) 2011-03-03 US disclosed
WO-2011025635-A2 COSMETIC USES OF MODIFIED STRESSED YEAST EXTRACTS AND RELATED COMPOSITIONS AVON PRODUCTS, INC. (US) 2011-03-03 WO disclosed
US-7189419-B2 Use of active extracts to lighten skin, lips, hair, and/or nails AVON PRODUCTS, INC. (US) 2007-03-13 US disclosed
US-20060013782-A1 Use of active extracts to improve the appearance of skin, lips, hair and/or nails AVON PRODUCTS, INC. 2006-01-19 US disclosed
US-20040126344-A1 Compositions having glycolipid to lighten skin and alter post-inflammatory hyperpigmentation AVON PRODUCTS, INC. 2004-07-01 US disclosed
US-20040115146-A1 Use of active extracts to lighten skin, lips, hair and/or nails AVON PRODUCTS, INC. 2004-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10117821-B2 Topical lightening composition and methods of use thereof TYR, CUTA, TUBA1A TDP1 2436/4885EYA2 44/4885APP 3411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.